Zobrazeno 1 - 10
of 429
pro vyhledávání: ''
Autor:
Daniel L. Flynn, Jarnail Singh, Bryan D. Smith, César Serrano, Alfonso García-Valverde, Anu Gupta
Publikováno v:
Molecular Cancer Therapeutics. 20:1234-1245
The majority of gastrointestinal stromal tumors (GIST) harbor constitutively activating mutations in KIT tyrosine kinase. Imatinib, sunitinib, and regorafenib are available as first-, second-, and third-line targeted therapies, respectively, for meta
Autor:
Sung Chul Lim, Youngnam Cho, Y. J. Kim, Seungmin Kang, Kyu Min Kim, Moon-Chang Baek, Keon Wook Kang, Miso Park, Ju Hyun Bae, Sung Baek Jeong, Jin Ki Kim, Dae Won Jun, Yong June Choi, Seung-Hyun Lee, Jiwon Kim, Wankyu Kim, HyungJae Lee, Sung Yun Cho
Publikováno v:
Cancer Research. 81:3539-3553
Extracellular vesicles (EV) in the tumor microenvironment have emerged as crucial mediators that promote proliferation, metastasis, and chemoresistance. However, the role of circulating small EVs (csEV) in cancer progression remains poorly understood
Autor:
Eunice Y. Lau, Man Tong, Katherine Po Sin Chung, Terence K. Lee, Stephanie Ma, Rainbow Wing Hei Leung, Etienne H. Mok, Irene Oi-Lin Ng, Martina Mang Leng Lei, Q Zhao, Vincent W. Keng, Carmen Oi Ning Leung, Hoi Wing Leung, Cong Ma
Publikováno v:
Cancer Research. 81:3229-3240
The survival benefit derived from sorafenib treatment for patients with hepatocellular carcinoma (HCC) is modest due to acquired resistance. Targeting cancer stem cells (CSC) is a possible way to reverse drug resistance, however, inhibitors that spec
Autor:
Pelin Gülizar Ersan, Hong Pei, Joel Linden, Sara Serra, Kim Phan, Qiping Zhao, Caglar Cekic, Renee Clift, H. Michael Shepard, Lei Huang, Michael J. LaBarre, Mertkaya Aras, Christopher D. Thanos, Lin Wang, Ozgur Sahin, Jessica Cowell, Xiaoming Li, Silvia Deaglio, Luz Marina Londoño, Ozge Saatci
Publikováno v:
Cancer Research. 81:3319-3332
Extracellular adenosine in tumors can suppress immune responses and promote tumor growth. Adenosine deaminase 2 (ADA2) converts adenosine into inosine. The role of ADA2 in cancer and whether it can target adenosine for cancer therapy has not been inv
Autor:
Marcos Galán-Ganga, Alberto J. Schuhmacher, Paula Nogales, Fatima Al-Shahrour, Miguel Jiménez-Alcázar, Lucía Zhu, Javier Perales-Patón, Scott W. Lowe, Álvaro Curiel-García, Massimo Squatrito
Publikováno v:
Mol Cancer Ther
Glioblastoma (GBM) is the most frequent and aggressive primary tumor type in the central nervous system in adults. Resistance to chemotherapy remains one of the major obstacles in GBM treatment. Identifying and overcoming the mechanisms of therapy re
Autor:
Rita Mitra, Tatiana M. Oberyszyn, Xiaokui Mo, Madhavi Bhat, Sara B. Peters, Kai Lu, Sujit Basu, Partha Sarathi Dasgupta
Publikováno v:
Cancer Prev Res (Phila)
Although the role of dopamine (DA) in malignant tumors has been reported, its function in premalignant lesions is unknown. Herein we report that the stimulation of DA D2 receptors in endothelial cells in ultraviolet B (UVB)-induced cutaneous lesions
Autor:
Samuel Achilefu, Michael H. Ross, Jingyu Xiang, Kristin A. Kwakwa, Elizabeth Cordell, Alison K. Esser, Vivek Sharma, Kristen Pagliai, Francesca Fontana, Jennifer L. Davis, Deborah J. Veis, Suzanne J. Bakewell, Xinming Su, Gregory M. Lanza, Katherine N. Weilbaecher, Gregory C. Fox, Christopher G. Maher, Jothilingam Sivapackiam, James A. J. Fitzpatrick, Yalin Xu, Ha X. Dang, Sheila A. Stewart
Publikováno v:
Mol Cancer Ther
Breast cancer bone metastases are common and incurable. Tumoral integrin β3 (β3) expression is induced through interaction with the bone microenvironment. Although β3 is known to promote bone colonization, its functional role during therapy of est
Autor:
Shawna Wall, Suzanne R. Thibodeaux, Vincent Hurez, T. L. Whiteside, Lishi Sun, Weiping Zou, Srilakshmi Pandeswara, Michael J. Brumlik, Tyler J. Curiel, Vinh Dao, Ilona Kryczek, Alvaro Padron, Brian B. Barnett, Benjamin J. Daniel, Justin M. Drerup
Publikováno v:
Clinical Cancer Research. 27:3661-3673
Purpose: Immunotherapy treats some cancers, but not ovarian cancer. Regulatory T cells (Tregs) impede anti-ovarian cancer immunity but effective human Treg-directed treatments are lacking. We tested Treg depletion with denileukin diftitox (DD) ± IFN
Autor:
Hsin-Fang Tu, Ming-Shyue Lee, Geen-Dong Chang, Santiago Ramón-Maiques, Chia-Chi Ku, Der-Yen Lee, Chao-Chi Ho, Hsin-Ying Lin, Ching-Tai Lee, Francisco Del Caño-Ochoa, Chun-Jung Ko, Ya-Hui Chuang, I-Chun Chen, Shao-Wei Lan, Hsin-Hsien Lin, Cheng-Fan Lee
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
13 páginas, 7 figuras
Current clinical trials of combined EGFR-tyrosine kinase inhibitors (TKI) and immune checkpoint blockade (ICB) therapies show no additional effect. This raises questions regarding whether EGFR-TKIs attenuate ICB-enhanced C
Current clinical trials of combined EGFR-tyrosine kinase inhibitors (TKI) and immune checkpoint blockade (ICB) therapies show no additional effect. This raises questions regarding whether EGFR-TKIs attenuate ICB-enhanced C
Autor:
Ki Hyun Yoo, Mi Hyeon Jang, Chang Hoon Cho, Alfredo Oliveros, Joseph A. Baur, Jason J. Tang, Mun Gyeong Bae, S. John Weroha, Jong Hoon Choi, Danielle Brogren, Xiaonan Hou, Mohammad Abdur Rashid, John R. Hawse, Ana Mia Corujo-Ramirez, Lindsey A Kirkeby
Publikováno v:
Cancer Res
Chemotherapy-induced cognitive impairment (CICI) is often reported as a neurotoxic side effect of chemotherapy. Although CICI has emerged as a significant medical problem, meaningful treatments are not currently available due to a lack of mechanistic